IFRX
InflaRx NV
NASDAQ · Healthcare · Biotechnology · DE
$1.45
+9.85%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.32
From 52W high−47.08%
Volume2.80M
Market cap$213.68M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.32
From 52W high
−47.08%
Volume
2.80M
Market cap
$213.68M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
32.6
MomentumView details →
1D Return
+9.85%
YTD Return
+42.57%
SummaryUpdated Jun 1, 2026
InflaRx N.V. (NASDAQ:IFRX) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Jena, Germany. Originally established as Fireman B.V., the company rebranded to InflaRx in 2017, the same year it went public on NASDAQ. The company specializes in discovering and developing novel therapeutics that target the complement system, specifically focusing on C5a inhibition technology to treat autoimmune and inflammatory diseases. InflaRx operates primarily in Germany and the United States, developing treatments for rare and debilitating conditions where significant unmet medical needs exist.
Similar companies
Latest newsMore news →